Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday ...

For all the attention on U.S.-China AI competition, new studies point to China's rapid rise in biotechnology, especially for ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

With finite natural resources and a growing demand for food, the world must find ways to overcome this challenge. One ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Brooklyn's business park in Sunset Park, Industry City, continues to see tenant demand. Biotech firms Cresilon and Rumi ...

Lamassu Biotech, a company with its “second headquarters” in Cleveland, has received a $2.7 million grant from the National ...